ASCO® 2024 Summary: "Gynecologic Oncology Updates"

2024 ASCO® Annual Meeting Insights Hub

R. Salani

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Adv…

2024 ESMO Annual Meeting Insights Hub

B. Monk

ASCO® 2024 Summary: "Gynecological Cancers Highlights"

2024 ASCO® Annual Meeting Insights Hub

M. Raza Mirza

Gynecologic Oncology Updates: Expert Perspective on Key Trial Findin…

Yale Cancer Center

E. Ratner

ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagn…

2024 ESMO Annual Meeting Insights Hub

B. Monk

Year in Review 2024 - Ovarian Cancer

Oncology 2024 Year in Review

E. Crane

ESMO 2024 Insights: PRIMA Trial - Newly Diagnosed Advanced Ovarian C…

ecancer

A. González-Martín

ESMO 2024 Insights: Mirvetuximab Soravtansine-gynx (MIRV) in Platinu…

2024 ESMO Annual Meeting Insights Hub

A. Secord

Management of Recurrent Ovarian Clear Cell Carcinoma

David Tan

Addressing the Critical Gaps in Relapsed Ovarian Cancer Management

Michael Birrer

Ovarian Cancer Patient Experience With Niraparib: Assessing QoL Data…

Erin Crane

Updates on Maintenance Therapy in Advanced Ovarian Cancer

Paul DiSilvestro

Antibody Drug Conjugates in Gynecologic Oncology: From Bench to Beds…

UCLA Health

G. Konecny

Precision Oncology in the Management of Ovarian Cancer

Miami Cancer Institute Precision Oncology Symposium

D. Dizon

ESMO 2024 Summary: Antibody Drug Conjugates (ADCs) - Identifying New…

2024 ESMO Annual Meeting Insights Hub

S. Banerjee

Genetic Testing in Determining Maintenance Treatment Options in Adva…

Alexander Olawaiye

Overview of Ovarian Cancer Updates

Masonic Cancer Center, University of Minnesota

J. Mattson

Treatment Options for Platinum-Sensitive Recurrent Ovarian Cancer

Richard Penson